RA
LFCR icon

Royce & Associates’s Lifecore Biomedical LFCR Stock Holding History

Royce & Associates’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-75,610
Closed -$401K – 899
2024
Q1 		$401K Hold
75,610
– – ﹤0.01% 803
2023
Q4 		$468K Hold
75,610
– – ﹤0.01% 795
2023
Q3 		$570K Hold
75,610
– – 0.01% 796
2023
Q2 		$731K Hold
75,610
– – 0.01% 789
2023
Q1 		$285K Hold
75,610
– – ﹤0.01% 873
2022
Q4 		$490K Hold
75,610
– – 0.01% 833
2022
Q3 		$672K Hold
75,610
– – 0.01% 785
2022
Q2 		$754K Hold
75,610
– – 0.01% 793
2022
Q1 		$876K Hold
75,610
– – 0.01% 820
2021
Q4 		$839K Hold
75,610
– – 0.01% 826
2021
Q3 		$697K Hold
75,610
– – 0.01% 859
2021
Q2 		$851K Hold
75,610
– – 0.01% 868
2021
Q1 		$801K Hold
75,610
– – 0.01% 883
2020
Q4 		$820K Hold
75,610
– – 0.01% 832
2020
Q3 		$735K Sell
75,610
-300,318
-80% -$2.86M 0.01% 809
2020
Q2 		$2.99M Buy
375,928
+36,900
+11% +$381K 0.03% 576
2020
Q1 		$2.95M Buy
339,028
+263,418
+348% +$2.74M 0.04% 507
2019
Q4 		$855K Sell
75,610
-84,262
-53% -$897K 0.01% 820
2019
Q3 		$1.74M Sell
159,872
-220,208
-58% -$2.4M 0.02% 732
2019
Q2 		$3.56M Sell
380,080
-528,798
-58% -$5.34M 0.03% 579
2019
Q1 		$11.2M Sell
908,878
-516,376
-36% -$6.3M 0.09% 309
2018
Q4 		$16.9M Buy
1,425,254
+31,490
+2% +$432K 0.15% 168
2018
Q3 		$20.1M Buy
1,393,764
+119,356
+9% +$1.65M 0.14% 209
2018
Q2 		$19M Buy
1,274,408
+40,217
+3% +$559K 0.13% 217
2018
Q1 		$16.1M Buy
1,234,191
+18,500
+2% +$243K 0.11% 255
2017
Q4 		$15.3M Sell
1,215,691
-1,200
-0.1% -$15.2K 0.1% 285
2017
Q3 		$15.8M Buy
1,216,891
+2,755
+0.2% +$36.3K 0.1% 273
2017
Q2 		$18M Buy
1,214,136
+176,629
+17% +$2.46M 0.12% 241
2017
Q1 		$12.4M Buy
1,037,507
+61,006
+6% +$772K 0.08% 325
2016
Q4 		$13.5M Sell
976,501
-8,500
-0.9% -$118K 0.09% 305
2016
Q3 		$13.2M Sell
985,001
-75,800
-7% -$918K 0.09% 309
2016
Q2 		$11.4M Buy
1,060,801
+36,200
+4% +$399K 0.08% 344
2016
Q1 		$10.8M Buy
1,024,601
+17,465
+2% +$192K 0.07% 375
2015
Q4 		$11.9M Sell
1,007,136
-118,625
-11% -$1.46M 0.07% 363
2015
Q3 		$13.1M Sell
1,125,761
-19,429
-2% -$257K 0.07% 357
2015
Q2 		$16.5M Buy
1,145,190
+77,702
+7% +$1.12M 0.07% 364
2015
Q1 		$14.9M Buy
1,067,488
+99,859
+10% +$1.38M 0.06% 426
2014
Q4 		$13.4M Buy
967,629
+424,997
+78% +$5.49M 0.05% 490
2014
Q3 		$6.65M Buy
542,632
+161,700
+42% +$2.02M 0.02% 742
2014
Q2 		$4.76M Buy
380,932
+305,322
+404% +$3.59M 0.01% 865
2014
Q1 		$844K Hold
75,610
– – ﹤0.01% 1169
2013
Q4 		$916K Hold
75,610
– – ﹤0.01% 1180
2013
Q3 		$922K Hold
75,610
– – ﹤0.01% 1183
2013
Q2 		$999K Buy
+75,610
New +$1.05M ﹤0.01% 1170

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Royce & Associates's LFCR Position: Q2 2024 in Review

Royce & Associates sold out of Lifecore Biomedical (LFCR) in Q2 2024, closing a stake of 75,610 shares — an estimated $401K sold.

Royce & Associates first reported a position in LFCR in Q2 2013 and held it in 44 quarters. The position peaked at $20.1M in Q3 2018. 75 funds tracked by Wall St. Rank hold LFCR as of Q2 2024.

  • Royce & Associates reported no remaining Lifecore Biomedical position as of Q2 2024 after selling out during the quarter.
  • Royce & Associates sold 75,610 Lifecore Biomedical shares in Q2 2024, an estimated $401K.
  • Royce & Associates first reported a position in Lifecore Biomedical in Q2 2013 and held it in 44 quarters.
  • Royce & Associates's Lifecore Biomedical position peaked at $20.1M in Q3 2018.
  • 75 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2024.

Based on Royce & Associates's 13F filing for Q2 2024, filed 13 Aug 2024.